drugset
drugset / Trial / NCT03970031

A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

NCT03970031 ↗

Phase 3 Unknown 1800 enrolled Cirius Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.

Timeline

Start
2022-06
Primary completion
2024-09
Completion
2024-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator MSDC-0602K Unknown — Oral

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis type 2 diabetes mellitus